Navigation Links
Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors

IRVING, Texas, Oct. 14, 2011 /PRNewswire/ -- Reata Pharmaceuticals, Inc. announced Friday a significant expansion of its management team to support the company's lead program, bardoxolone methyl, and to continue advancing its earlier-stage pipeline.

Joining the company are the following executives:

  • Paul Audhya, MD, as Vice President of Development and Chief Medical Officer;
  • Hilary Malone, Ph.D., as Vice President and Chief Regulatory and Compliance Officer;
  • Sean Nolan as Vice President and Chief Commercial Officer; and
  • Jim Rouse as Vice President and Chief Information Officer.

The company also announced the addition of Nancy Wysenski -- who is Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals -- to Reata's board of directors.

"This is an exciting period of growth for Reata," CEO Warren Huff said. "Bringing these talented leaders on board is a significant step toward our goal of building a stand-alone, fully integrated biopharmaceutical company."

Paul Audhya, MD, Vice President of Development and Chief Medical Officer. Dr. Audhya joins Reata with over 15 years of biopharmaceutical R&D experience. He led drug development in multiple therapeutic areas, including renal disease, at Johnson & Johnson, The Liposome Company, Bristol-Myers Squibb, Amgen, and Abbott Laboratories. He earned his bachelor's degrees at New York University, his doctorate at New York University School of Medicine, and his MBA from the Graziadio School of Business and Management at Pepperdine University. He completed his residency in internal medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ).

Hilary Malone, Ph.D., Vice President and Chief Regulatory and Compliance Officer. Dr. Malone comes to Reata from Pfizer Inc, where she was Senior Vice President and Head of Worldwide Regulatory Strategy from 2009 to 2011. Previously, she was Senior Vice President and Head of Global Regulatory Affairs and Compliance at Wyeth, beginning in 2006 until the company was acquired by Pfizer in 2009. Earlier in her career, she held positions of increasing responsibility at SmithKline Beecham, GlaxoSmithKline and AstraZeneca. Dr. Malone earned her bachelor of science in physiology and her doctorate in molecular neuropharmacology from the University of Dundee, Scotland, UK.

Sean Nolan, Vice President and Chief Commercial Officer. Mr. Nolan brings to Reata 20 years of pharmaceutical industry experience. He began his career at Abbott Laboratories and served in a variety of marketing and sales leadership positions across the organization. In 2004, Mr. Nolan joined the executive team at Ovation Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of therapies to treat rare and severe diseases. The company was acquired by the Danish pharmaceutical company, H. Lundbeck, in 2009 and after leading the company integration, he served as President of the newly created US entity.

Jim Rouse, Vice President and Chief Information Officer. Mr. Rouse joins Reata with extensive experience in the life sciences industry. Most recently, he was executive director of information technology at PharmaNet Development Group. Previously, he worked at RES Partners, Pharmacopeia, and Covance. He began his career at Bristol-Myers Squibb, remaining with the company for 25 years and leading many complex business and technology initiatives. Mr. Rouse has a bachelor of science in commerce and management science from Rider University and a master's degree in information management from Stevens Institute of Technology.

Nancy Wysenski, Member, Board of Directors. Ms. Wysenski is currently the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer at Endo Pharmaceuticals. Previously, she was a co-founder of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc.

About Reata Pharmaceuticals

Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes. Activation of this important biological target is thought to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing bardoxolone methyl, its lead product candidate, to prevent progression of chronic kidney disease (CKD). Bardoxolone methyl is currently in a global Phase 3 clinical trial in patients with Stage 4 CKD and type 2 diabetes.

For more information, please visit the company's Web site at

Reata Contacts

Media: Matt Middleman or David Schull,, 212-845-4272;, 212-845-4271
Investors: Alan Roemer,, 1-646-378-2945

SOURCE Reata Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
2. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
3. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
4. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
5. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
6. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
7. Cumberland Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 3, 2011
8. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):